TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03706365
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02040207
Drug: AM-101
Normalized name: CAM-101
DrugBank: CAM-101 (DB18414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-101 gel for intratympanic injection
Study: NCT02476760
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study: NCT04128748
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04128748
Drug: Quizartinib
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02783300
Drug: GSK3326595
Normalized name: Protein arginine methyltransferase 5 inhibitor gsk3326595
DrugBank: Pemrametostat (DB19170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3326595 will be administered with and without food, in tablet and capsule formulation.
Study: NCT02783300
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered.
Study: NCT02476760
Drug: GLP-1 analogs
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
Study: NCT02476760
Drug: Biguanides
Normalized name: Biguanides
DrugBank: Biguanide (DB13100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study: NCT04128787
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole capsules
Study: NCT01392521
Drug: Copanlisib + Refametinib (BAY86-9766)
DrugBank: Refametinib (DB06309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
Study: NCT01392521
Drug: Copanlisib + Refametinib (BAY86-9766)
DrugBank: Refametinib (DB06309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
Study: NCT02891616
Drug: fludeoxyglucose F 18
Normalized name: FLUDEOXYGLUCOSE F 18
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03535272
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
Study: NCT00593099
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BUP \[as the intermediate-release (IR) formulation\] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg \[as BUP SR formulation\] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
Study: NCT03737851
Drug: elezanumab
Normalized name: Elezanumab
DrugBank: Elezanumab (DB15240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for infusion
Study: NCT04434170
Drug: Sacubitril-Valsartan
Normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: outpatients who start treatment with sacubitril/valsartan according to guidelines will andergo cardiopulmonary exercise testing evaluation
Study: NCT01042782
Drug: RAD001 and MitomycinC
Normalized name: cytarabine and daunorubicin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks
Study: NCT00727532
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg by mouth twice daily for 28 consecutive days
Study: NCT03036800
Drug: Saxenda
Normalized name: Saxenda
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
Study: NCT01077154
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered subcutaneously for up to 5 years
Study: NCT01432782
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
Study: NCT00148473
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02374931
Drug: F-18 16 Alpha-Fluoroestradiol
Normalized name: F-18 16 alpha-Fluoroestradiol
DrugBank: Fluoroestradiol F-18 (DB15690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo 18F-FES PET/CT
Study: NCT01067547
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
Study: NCT02653261
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
Study: NCT00333346
Drug: Administration of tramadol intravenously
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00859027
Drug: risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 mg/week by mouth
Study: NCT00388674
Drug: entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily, Investigator/Patient decision
Study: NCT02454322
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
Study: NCT03608696
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine 0.075 mg/ml solution
Study: NCT03926624
Drug: DFP-10917
Normalized name: DFP
DrugBank: Isoflurophate (DB00677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
Study: NCT03926624
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cytosine arabinoside (ara-C)
Study: NCT03926624
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine
Study: NCT03926624
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine
Study: NCT03926624
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone
Study: NCT03926624
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide
Study: NCT03926624
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine
Study: NCT03926624
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin
Study: NCT03926624
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax
Study: NCT03926624
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine
Study: NCT04945629
Drug: Alveolar ridge preservation with a PRP (PRGF-Endoret)
Normalized name: PreserVision with Lutein
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filling of the alveolus with PRGF clot and fibrin plug.
Study: NCT03398876
Drug: Oromucosal Nicotine Spray (ONS)
Normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive oral dose of oromucosal nicotine spray (ONS).
Study: NCT03398876
Drug: Nicotine Gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will chew nicotine gum for 30 minutes.
Study: NCT03543969
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 450 mg encorafenib daily by mouth
Study: NCT03543969
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45 mg binimetinib daily by mouth
Study: NCT03543969
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg Nivolumab IV every 2 weeks
Study: NCT02386553
Drug: Nusinersen
Normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for intrathecal injection
Study: NCT03220022
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03220022
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03220022
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03220022
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03892616
Drug: BI 1358894 (B)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation 2 (TF2a), fed
Study: NCT03892616
Drug: BI 1358894 (C)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation 2 (TF2a), fasted
Study: NCT03892616
Drug: BI 1358894 (D)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation 2 (TF2b), fed
Study: NCT03892616
Drug: BI 1358894 (E)
Normalized name: (E)-3,4-bis(4-hydroxyphenyl)-3-hexene
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet formulation 2 (TF2b), fasted
Study: NCT03892616
Drug: BI 1358894 (A)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation 1 (TF1), fed
Study: NCT03826901
Drug: delgocitinib
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cream for topical application
Study: NCT04531059
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proton pump inhibitor
Study: NCT04531059
Drug: Bismuth Potassium Citrate
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT00612495
Drug: oxaliplatin, 5 FU
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin:130 mg/m² as a 2-hour intravenous (IV) infusion in 500 mL of 5% glucose solution on Day 1 and repeated every 3 weeks.~5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 to Day 4, repeated every 3 weeks.
Study: NCT00822679
Drug: Eszopiclone
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
Study: NCT01266720
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.
Study: NCT01653379
Drug: DP001
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
Study: NCT00116259
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02403687
Drug: baclofen 2%
Normalized name: Baclofen 2% Topical application Cream
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT02403687
Drug: Bupivacaine hydrochloride 1%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT02403687
Drug: Cyclobenzaprine hydrochloride 2%
Normalized name: EnovaRX - Cyclobenzaprine Hydrochloride 2% in Microderm External Cream Compounding Kit
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT02403687
Drug: Gabapentin 6%
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT02403687
Drug: Ketamine 10%
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT02403687
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT02403687
Drug: Prilocaine 2.5%
Normalized name: LIDOCAINE 2.5/PRILOCAINE 2.5% CREAM
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT00504842
Drug: MRX-801
Normalized name: MRx-4DP0004
DrugBank: MRx-4DP0004 (DB15751)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00438932
Drug: Lanthanum Carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate 1000mg 3x/day
Study: NCT02403687
Drug: Sumatriptan 5%
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT02403687
Drug: Tizanidine 0.1%
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT02403687
Drug: Topiramate 2.5%
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: compound topical cream
Study: NCT02403687
Drug: Capsaicin, USP 0.0375%
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT00781612
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered as per local prescribing information.
Study: NCT00781612
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered as per local prescribing information.
Study: NCT00781612
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
Study: NCT00781612
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab will be administered as per local prescribing information.
Study: NCT00781612
Drug: Trastuzumab Emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
Study: NCT00781612
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)
Study: NCT01068795
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
Study: NCT00955760
Drug: Neramexane
Normalized name: Neramexane
DrugBank: Neramexane (DB04926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Drug Interaction Study
Study: NCT02403687
Drug: Menthol, NF 5.00 %
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT00333203
Drug: Next Generation Ophthalmic Irrigating Solution (NGOIS)
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Volume sufficient to irrigate adequately during cataract surgery
Study: NCT03568929
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets administered according to the product information and treatment guidelines in routine clinical practice
Study: NCT04254731
Drug: Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)
Normalized name: levomethadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00354731
Drug: pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
Study: NCT00200473
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01508325
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (\>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was \>=90 mmHg measured every 4 weeks.
Study: NCT01508325
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was \>=140 mmHg and/or DBP was \>=90 mmHg measured every 4 weeks.
Study: NCT04682639
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
Study: NCT01554488
Drug: Inhaled Fluticasone Propionate
Normalized name: fluticasone propionate Inhalant Product
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled corticosteroid
Study: NCT02129205
Drug: PF-06650808
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation Phase \[Part 1\] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
Study: NCT02129205
Drug: PF-06650808
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Expansion Phase \[Part 2\] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
Study: NCT00601250
Drug: linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive linagliptin 5 mg tablets once daily
Study: NCT04682639
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
Study: NCT00883740
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
Study: NCT00769158
Drug: Topiramate and Naltrexone
Normalized name: bupropion and naltrexone
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 200 mg and Naltrexone 50 mg
Study: NCT01818414
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mcg of buccal misoprostol, 3 hours prior to planned D\&E